Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies in oncology and obesity. Its pipeline centers on CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer, and CRB-913, a peripherally restricted CB1 receptor inverse agonist designed for obesity treatment.

8.07

8.07

— Corbus Pharmaceuticals Holdings, Inc.
%
Oncology pipeline50% Includes CRB-701 and related cancer-focused development programs targeting solid tumors.
Obesity pipeline30% Includes CRB-913, a CB1 receptor program aimed at weight-loss treatment.
Preclinical antibody programs15% Includes CRB-601 and other early-stage biologics under development.
Research and development services5% Internal R&D, clinical operations, and regulatory development activities supporting the pipeline.

Corbus does not currently sell commercial products, so its near-term 'customers' are primarily clinical investigators,...

  • Clinical trial ecosystemprimary

    Hospitals, investigators, and CROs that support enrollment, dosing, monitoring, and data collection for CRB-701, CRB-913, and CRB-601.

  • Regulatory authoritiesprimary

    FDA and comparable agencies that determine whether product candidates can advance to later-stage trials or approval.

  • Pharma development partnerssecondary

    Potential licensing or collaboration partners that may fund development, share risk, or commercialize assets.

  • Future oncology prescribersemerging

    Oncologists who would prescribe CRB-701 if it reaches approval and demonstrates clinical benefit.

  • Future obesity prescribersemerging

    Physicians treating obesity who could adopt CRB-913 if safety and efficacy are validated.

Corbus is headquartered in Norwood, Massachusetts and operates as a U.S.-based clinical-stage company...

  • •Headquartered in Norwood, Massachusetts, United States
  • •Most cash and operating resources are held in the U.S.
  • •Clinical trials may involve sites and vendors outside the U.S.
  • •No country revenue disclosure because the company has no product sales
  • •Future commercialization could broaden exposure beyond the U.S.

Corbus is focused on advancing a small number of high-conviction pipeline assets rather than managing a broad...

01
Advance CRB-701 clinical developmentshort-term

The oncology asset is a core value driver and needs human data to support partnering or later-stage trials.

02
Progress CRB-913 obesity programshort-term

The obesity market is large, but the program must prove safety and tolerability to differentiate from competitors.

03
Secure external fundingshort-term

The company has no product revenue and expects continued operating losses, so capital access is essential.

Corbus is exposed to the classic risks of an early-stage biotech: no product revenue, high cash burn, and uncertainty...

critical

Lack of product revenue

The company has not commercialized any products, so value depends on future clinical and regulatory success.

Scope
All current operations
Materiality
high
high

Funding and dilution risk

Ongoing R&D and clinical costs require repeated capital raises, which may be unavailable or dilutive.

Scope
Equity financing and cash runway
Materiality
high
high

Clinical development failure

Drug candidates may not show sufficient safety or efficacy in trials, which would impair commercialization prospects.

Scope
CRB-701, CRB-913, CRB-601
Materiality
high
high

Third-party manufacturing and trial execution

The company relies on external manufacturers and service providers to produce clinical material and run studies.

Scope
Supply chain, quality, timelines
Materiality
medium
medium

Competitive pressure

Larger biopharma companies and other biotech firms are pursuing similar oncology and obesity mechanisms.

Scope
Nectin-4 ADCs, CB1 obesity drugs
Materiality
medium
medium

Geopolitical and trade exposure

Management disclosed that U.S.-China trade relations and broader geopolitical conditions could affect operations and results.

Scope
Global supply and development ecosystem
Materiality
medium
Accrued research and development expense
Can shift expense timing between quarters
Stock-based compensation
Affects operating loss and diluted share metrics
License milestone obligations
Can create contingent liabilities and cash outflows
Fair value of cash equivalents and investments
Affects other income and liquidity presentation

Corvus Pharmaceuticals, Inc.

CRVS · Pharmaceutical Preparations

CRESCENT BIOPHARMA, INC.

CBIO · Pharmaceutical Preparations

NextCure, Inc.

NXTC · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

: 28/04/2026